Crofelemer Powder for Oral Solution

DRUG2 trials

Sponsors

Napo Pharmaceuticals, Inc., Napo Therapeutics, S.p.A.

Conditions

Congenital DisordersFunctional Gastrointestinal DisordersMalabsorption SyndromesMicrovillus Inclusion DiseasePost-Op ComplicationRare DiseasesShort Bowel SyndromeShort Gut Syndrome

Phase 2

Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

Active, not recruitingNCT06721871

Napo Pharmaceuticals, Inc.Congenital Disorders, Microvillus Inclusion Disease, Rare Diseases

Start: 2025-05-01End: 2026-12-01Updated: 2026-06-09

Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

RecruitingNCT06904872

Napo Therapeutics, S.p.A.Functional Gastrointestinal Disorders, Malabsorption Syndromes, Post-Op Complication +2

Start: 2025-05-29End: 2027-03-01Target: 18Updated: 2026-06-09